Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myelogenous leukemia: a review

J E Cortes1, M Talpaz, H Kantarjian

  • 1Department of Hematology, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA.

The American Journal of Medicine
|May 1, 1996
PubMed
Summary

Chronic myelogenous leukemia (CML) is a blood cancer characterized by the Philadelphia chromosome. Treatment options are evolving, with interferon alpha showing survival advantages and bone marrow transplantation offering potential cures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.

Blood·2020
Same author

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Blood·2020
Same author

Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates.

The pharmacogenomics journal·2017
Same author

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.

Leukemia·2017
Same author

Influence of IDH on FLT3-ITD status in newly diagnosed AML.

Leukemia·2017

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Chronic myelogenous leukemia (CML) is a myeloproliferative disorder with a progressive course.
  • The Philadelphia chromosome (t(9;22)) is a hallmark genetic abnormality in CML.
  • Traditional treatments like hydroxyurea offer limited long-term remission.

Purpose of the Study:

  • To review current and alternative therapies for CML.
  • To analyze the efficacy of interferon alpha (IFN-alpha) and bone marrow transplantation (BMT).
  • To discuss the impact of molecular detection of minimal residual disease.

Main Methods:

  • Review of existing studies on CML treatment modalities.
  • Comparison of outcomes between conventional chemotherapy, IFN-alpha, and BMT.
  • Analysis of data on molecular detection of the Philadelphia chromosome.

Main Results:

  • Interferon alpha demonstrates a survival advantage over conventional chemotherapy.
  • Allogeneic bone marrow transplantation can be curative but has limitations.
  • Sensitive molecular techniques detect minimal residual disease, aiding treatment assessment.

Conclusions:

  • IFN-alpha represents a significant advancement in CML therapy.
  • BMT remains a curative option for select CML patients.
  • Further research into novel agents and treatment strategies is ongoing.

Related Experiment Videos